Welcome to our dedicated page for BIOVAXYS TECHNOLOGY news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on BIOVAXYS TECHNOLOGY stock.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform. They focus on treating cancers, infectious diseases, antigen desensitization, and other immunological fields. The company has a range of products in their clinical stage pipeline, including maveropepimut-S and BVX-0918, which target different types of cancers like Diffuse Large B Cell Lymphoma (DLBCL) and ovarian cancer. BioVaxys also capitalizes on its tumor immunology expertise to identify new targetable tumor antigens using predictive algorithms and other technologies.
BioVaxys Technology Corp. (OTCQB: BVAXF) has signed a binding Letter of Intent with AP Visionaries, Inc. to jointly develop a DPX™-based therapy for life-threatening food allergies, specifically peanut/tree nuts and eggs. The collaboration involves The Schroeder Allergy and Immunology Research Institute at McMaster University. BioVaxys will fund the study and retain intellectual property rights, while APVI will receive royalties and milestone payments.
The global peanut allergy treatment market is expected to reach USD 1.01 billion by 2030, growing at a CAGR of 11.82% from 2024 to 2030. Peanut allergies affect about 1.2% of the US population and 2.5% of children, with an estimated annual economic cost of $24.8 billion for food allergies in US children.
The DPX™ platform's flexibility and immune-educating capability offer potential advantages over current treatments, which often require frequent dosing and carry risks of anaphylaxis.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has been issued U.S. Patent No. 12,042,537 by the USPTO for inducing an antibody immune response using a low dose volume delivery of a B-cell epitope formulated with DPX™. This proprietary lipid-based delivery platform allows for a robust and long-duration immune response. The technology enables delivery of less than 100 µl, packaging 5-50 µL of an antigen.
Potential applications include epitope-based vaccines for chronic hepatitis-B, influenza, and RSV. A previous Phase 1 study of DPX-RSV showed promising results, with 93% of participants maintaining antigen-specific immune responses after nine months. This patent issuance strengthens BioVaxys' position for further development and potential partnerships in epitope-based vaccine development.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has engaged Brittany Davison, CPA, CA as Business Advisor. Ms. Davison, owner of Davison CPA Consulting Inc., previously served as Chief Accounting Officer and Acting CFO at IMV Inc., where she led a US$9M Public Offering and assisted in raising over US$165M. She was instrumental in IMV Inc.'s Nasdaq listing in 2018 and involved in business development and investor relations. At BioVaxys, Ms. Davison will assist with knowledge transfer of former IMV Inc. assets, support investor relations, business development, and facilitate private funding, government funding, and SR&ED tax incentives.
BioVaxys Technology Corp. (BVAXF) and SpayVac-for-Wildlife, Inc. have announced a trial to test SpayVac®, a long-lasting, single-dose contraceptive vaccine, in captive Asian elephants. The trial, conducted in partnership with Chiang Mai University in Thailand, aims to address concerns about human-elephant conflicts and ecological impacts due to confined elephant populations. SpayVac utilizes BioVaxys' patented liposome-based antigen delivery platform, which has shown sustained immune responses in various species.
The research, which began in April, will track reproductive cycling, contraceptive efficacy, and antibody titers over a 5-year period. A previous trial with African elephants demonstrated elevated antibody titers for at least 7 years after a single dose. SpayVac is also planning to commercialize fertility control vaccines for other animals using the same technology.
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTC: BVAXF) announced the revocation of a cease trade order issued by the Ontario Securities Commission (OSC) on May 15, 2024. The order was due to delays in filing audited annual financial statements for the year ended October 31, 2023, and interim financial statements for the three months ended January 31, 2024. The company has now completed these filings, along with interim financial statements for the six months ended April 30, 2024. The OSC confirmed the order revocation on July 11, 2024, with all filings available on SEDAR+.
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) has been issued a Failure-to-File Cease Trade Order (FFCTO) by the Ontario Securities Commission (OSC) due to delays in filing required financial statements and discussions for the fiscal year ending October 31, 2023, and the three months ending January 31, 2024. The FFCTO, effective May 15, 2024, prohibits any trading of BioVaxys securities in Canada. The company missed deadlines of February 28, 2024, for annual filings and April 1, 2024, for interim filings. They are working to complete these filings soon and expect the FFCTO to be lifted once compliance is achieved.
BioVaxys Technology Corp. appoints Christopher Cherry as Chief Financial Officer, bringing extensive experience in financial management. The company anticipates significant growth following the recent acquisition of IMV Intellectual Property.
FAQ
What is the current stock price of BIOVAXYS TECHNOLOGY (BVAXF)?
What is the market cap of BIOVAXYS TECHNOLOGY (BVAXF)?
What is BioVaxys Technology Corp focused on?
What are some products in BioVaxys' clinical stage pipeline?
How does BioVaxys identify new targetable tumor antigens?
